MEIP Stock Overview
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.
MEI Pharma, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.24|
|52 Week High||US$2.80|
|52 Week Low||US$0.23|
|1 Month Change||-20.26%|
|3 Month Change||-55.78%|
|1 Year Change||-90.71%|
|3 Year Change||-87.57%|
|5 Year Change||-88.57%|
|Change since IPO||-99.95%|
Recent News & Updates
Need To Know: Analysts Are Much More Bullish On MEI Pharma, Inc. (NASDAQ:MEIP)Nov 19
We're Hopeful That MEI Pharma (NASDAQ:MEIP) Will Use Its Cash WiselyMay 18
Need To Know: The Consensus Just Cut Its MEI Pharma, Inc. (NASDAQ:MEIP) Estimates For 2022Mar 26
Newsflash: MEI Pharma, Inc. (NASDAQ:MEIP) Analysts Have Been Trimming Their Revenue ForecastsFeb 12
Need To Know: Analysts Just Made A Substantial Cut To Their MEI Pharma, Inc. (NASDAQ:MEIP) EstimatesDec 02
We're Not Very Worried About MEI Pharma's (NASDAQ:MEIP) Cash Burn RateNov 04
The Independent Non-Executive Director of MEI Pharma, Inc. (NASDAQ:MEIP), Frederick Driscoll, Just Sold 40% Of Their HoldingFeb 25
New Forecasts: Here's What Analysts Think The Future Holds For MEI Pharma, Inc. (NASDAQ:MEIP)Feb 11
MEI Pharma (NASDAQ:MEIP) Shareholders Have Enjoyed An Impressive 121% Share Price GainJan 15
What Can We Learn About MEI Pharma's (NASDAQ:MEIP) CEO Compensation?Dec 11
|MEIP||US Biotechs||US Market|
Return vs Industry: MEIP underperformed the US Biotechs industry which returned -11.2% over the past year.
Return vs Market: MEIP underperformed the US Market which returned -21.2% over the past year.
|MEIP Average Weekly Movement||15.4%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: MEIP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: MEIP's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome.
MEI Pharma, Inc. Fundamentals Summary
|MEIP fundamental statistics|
Is MEIP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MEIP income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.40|
|Net Profit Margin||-128.55%|
How did MEIP perform over the long term?See historical performance and comparison